Improving the Therapeutic Profile of MSCs: Cytokine Priming Reduces Donor-dependent Heterogeneity and Enhances Their Immunomodulatory Capacity

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2025 Mar 4

PMID 40034706

Authors

Jaris Valencia

Rosa M Yanez

Sandra Muntion

Maria Fernandez-Garcia

Jorge Diego Martin-Rufino

Agustin G Zapata

Juan A Bueren

Angeles Vicente

Fermin Sanchez-Guijo

Affiliations

Soon will be listed here.

Abstract

Introduction: MSCs exhibit regenerative, anti-inflammatory and immunomodulatory properties due to the large amount of cytokines, chemokines and growth factors they secrete. MSCs have been extensively evaluated in clinical trials, however, in some cases their therapeutic effects are variable. Therefore, strategies to improve their therapeutic potential, such as preconditioning with proinflammatory factors, have been proposed. Several priming approaches have provided non-conclusive results, and the duration of priming effects on MSC properties or their response to a second inflammatory stimulus have not been fully addressed.

Methods: We have investigated the impact of triple cytokine priming in MSCs on their characterization and viability, their transcriptomic profile, the functionality of innate and acquired immune cells, as well as the maintenance of the response to priming over time, their subsequent responsiveness to a second inflammatory stimulus.

Results: Priming MSCs with proinflammatory cytokines (CK-MSCs) do not modify the differentiation capacity of MSCs, nor their immunophenotype and viability. Moreover, cytokine priming enhances the anti-inflammatory and immunomodulatory properties of MSCs against NK and dendritic cells, while maintaining the same T cell immunomodulatory capacity as unstimulated MSCs. Thus, they decrease T-lymphocytes and NK cell proliferation, inhibit the differentiation and allostimulatory capacity of dendritic cells and promote the differentiation of monocytes with an immunosuppressive profile. In addition, we have shown for the first time that proinflammatory priming reduces the variability between different donors and MSC origins. Finally, the effect on CK-MSC is maintained over time and even after a secondary inflammatory stimulus.

Conclusions: Cytokine-priming improves the therapeutic potential of MSCs and reduces inter-donor variability.

References

Zhao K, Lin R, Fan Z, Chen X, Wang Y, Huang F . Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial. J Hematol Oncol. 2022; 15(1):22. PMC: 8900437. DOI: 10.1186/s13045-022-01240-4. View

Li J, Wu Z, Zhao L, Liu Y, Su Y, Gong X . The heterogeneity of mesenchymal stem cells: an important issue to be addressed in cell therapy. Stem Cell Res Ther. 2023; 14(1):381. PMC: 10734083. DOI: 10.1186/s13287-023-03587-y. View

Kurtzberg J, Abdel-Azim H, Carpenter P, Chaudhury S, Horn B, Mahadeo K . A Phase 3, Single-Arm, Prospective Study of Remestemcel-L, Ex Vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells for the Treatment of Pediatric Patients Who Failed to Respond to Steroid Treatment for Acute Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2020; 26(5):845-854. PMC: 8322819. DOI: 10.1016/j.bbmt.2020.01.018. View

Duijvestein M, Wildenberg M, Welling M, Hennink S, Molendijk I, van Zuylen V . Pretreatment with interferon-γ enhances the therapeutic activity of mesenchymal stromal cells in animal models of colitis. Stem Cells. 2011; 29(10):1549-58. DOI: 10.1002/stem.698. View

Fisher S, Cutler A, Doree C, Brunskill S, Stanworth S, Navarrete C . Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition. Cochrane Database Syst Rev. 2019; 1:CD009768. PMC: 6353308. DOI: 10.1002/14651858.CD009768.pub2. View

Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts A . Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell. 2008; 2(2):141-50. DOI: 10.1016/j.stem.2007.11.014. View

Fernandez-Santos M, Garcia-Arranz M, Andreu E, Garcia-Hernandez A, Lopez-Parra M, Villaron E . Optimization of Mesenchymal Stromal Cell (MSC) Manufacturing Processes for a Better Therapeutic Outcome. Front Immunol. 2022; 13:918565. PMC: 9261977. DOI: 10.3389/fimmu.2022.918565. View

Wang Q, Yang Q, Wang Z, Tong H, Ma L, Zhang Y . Comparative analysis of human mesenchymal stem cells from fetal-bone marrow, adipose tissue, and Warton's jelly as sources of cell immunomodulatory therapy. Hum Vaccin Immunother. 2015; 12(1):85-96. PMC: 4962749. DOI: 10.1080/21645515.2015.1030549. View

Lacey D, Simmons P, Graves S, Hamilton J . Proinflammatory cytokines inhibit osteogenic differentiation from stem cells: implications for bone repair during inflammation. Osteoarthritis Cartilage. 2009; 17(6):735-42. DOI: 10.1016/j.joca.2008.11.011. View

10.

Duffy M, Ritter T, Ceredig R, Griffin M . Mesenchymal stem cell effects on T-cell effector pathways. Stem Cell Res Ther. 2011; 2(4):34. PMC: 3219065. DOI: 10.1186/scrt75. View

11.

Wang J, Liu Y, Ding H, Shi X, Ren H . Mesenchymal stem cell-secreted prostaglandin E ameliorates acute liver failure via attenuation of cell death and regulation of macrophage polarization. Stem Cell Res Ther. 2021; 12(1):15. PMC: 7792134. DOI: 10.1186/s13287-020-02070-2. View

12.

Sabio G, Davis R . TNF and MAP kinase signalling pathways. Semin Immunol. 2014; 26(3):237-45. PMC: 4099309. DOI: 10.1016/j.smim.2014.02.009. View

13.

Krzyszczyk P, Schloss R, Palmer A, Berthiaume F . The Role of Macrophages in Acute and Chronic Wound Healing and Interventions to Promote Pro-wound Healing Phenotypes. Front Physiol. 2018; 9:419. PMC: 5938667. DOI: 10.3389/fphys.2018.00419. View

14.

Song N, Scholtemeijer M, Shah K . Mesenchymal Stem Cell Immunomodulation: Mechanisms and Therapeutic Potential. Trends Pharmacol Sci. 2020; 41(9):653-664. PMC: 7751844. DOI: 10.1016/j.tips.2020.06.009. View

15.

Gao Q, Jia F, Li X, Kong Y, Tian Z, Bi L . Biophysical cues to improve the immunomodulatory capacity of mesenchymal stem cells: The progress and mechanisms. Biomed Pharmacother. 2023; 162:114655. DOI: 10.1016/j.biopha.2023.114655. View

16.

Lee B, Kang K . Functional enhancement strategies for immunomodulation of mesenchymal stem cells and their therapeutic application. Stem Cell Res Ther. 2020; 11(1):397. PMC: 7491075. DOI: 10.1186/s13287-020-01920-3. View

17.

Klinker M, Wei C . Mesenchymal stem cells in the treatment of inflammatory and autoimmune diseases in experimental animal models. World J Stem Cells. 2015; 7(3):556-67. PMC: 4404391. DOI: 10.4252/wjsc.v7.i3.556. View

18.

Garcia-Bernal D, Garcia-Arranz M, Yanez R, Hervas-Salcedo R, Cortes A, Fernandez-Garcia M . The Current Status of Mesenchymal Stromal Cells: Controversies, Unresolved Issues and Some Promising Solutions to Improve Their Therapeutic Efficacy. Front Cell Dev Biol. 2021; 9:650664. PMC: 8007911. DOI: 10.3389/fcell.2021.650664. View

19.

Chinnadurai R, Copland I, Patel S, Galipeau J . IDO-independent suppression of T cell effector function by IFN-γ-licensed human mesenchymal stromal cells. J Immunol. 2014; 192(4):1491-501. DOI: 10.4049/jimmunol.1301828. View

20.

Liu C, Xu Y, Lu Y, Du P, Li X, Wang C . Mesenchymal stromal cells pretreated with proinflammatory cytokines enhance skin wound healing via IL-6-dependent M2 polarization. Stem Cell Res Ther. 2022; 13(1):414. PMC: 9375394. DOI: 10.1186/s13287-022-02934-9. View